Cantargia AB Employee Directory
Biotechnology ResearchSkåne County, Sweden11-50 Employees
Cantargia develops antibody based therapies against the target IL1RAP. The two clinical programs are nadunolimab in phase II development for treatment of cancer, and CAN10 in phase I development for autoimmune/inflammatory diseases.